Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB226 in Relapsed/Refractory Primary Mediastinal Large B-cell Lymphoma
CTR20181173Phase 2Active
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of geptanolimab in primary mediastinal large B-cell lymphoma (PMBCL), mature B-cell lymphoma, sponsored by Jacobio Pharmaceuticals. Started Aug 2018; status: active.
02
Drugs
geptanolimab
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)mature B-cell lymphoma
Beyond the preview
Go deeper on CTR20181173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181173.